Chronic myeloid leukaemia – a crucial change to the patient prognosis after an introduction of tyrosine kinase inhibitors

Czech version

Authors: H. Klamová
Authors‘ workplace: Ústav hematologie a krevní transfuze Praha, ředitel prof. MUDr. Marek Trněný, CSc.
Published in: Vnitř Lék 2012; 58(Suppl 2): 27-37
Category:

Overview

Chronic myeloid leukaemia (CML) is an example of a disease where new knowledge in molecular biology enabled thorough understanding of the nature of the disease as well as it led to a discovery of completely new, targeted treatment principle, i.e. inhibition of tyrosine kinase Bcr-Abl, now the main therapeutic target. Introduction of tyrosine kinase inhibitors (TKI) imatinib, dasatinib, nilotinib into clinical practice meant a revolutionary change to treatment strategy with a significant effect on survival and patient quality of life. A disease with originally fatal prognosis has changed in patients diagnosed in its chronic phase to a disease with expected median survival estimated at more than 25 years.

Key words:
chronic myeloid leukaemia – tyrosine kinase inhibitors – imatinib – dasatinib – nilotinib – interferone alpha

Sources

1. Hehlmann R, Hochhaus A, Baccarani M. European Leukemia Net. Chronic myeloid leukaemia. Lancet 2007; 370: 342–350.

2. Rohrbacher M, Berger U, Hochhaus A et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009; 23: 602–604.

3. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Brno: Masarykova univerzita 2005. Dostupné na: www: http://www.svod.cz.

4. Mužík J, Faber E. Epidemiologie. In: Faber E, Indrák K (eds). Chronická myeloidní leukemie. Praha: Galén Publishing 2010: 9–16.

5. Druker BJ, Tamura S, Buchdunger E et al. Effect of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.

6. Faderl S, Talpaz M, Estrov Z et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207–219.

7. Agami R, Blandino G, Oren M et al. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 1999; 399: 809–813.

8. Goldman JM, Green AR, Vannucchi AM et al. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 2009; 23: 1708–1715.

9. Faber E. Chronická myeloidní leukemie. In: Mayer J, Starý J et al (eds). Leukemie. Praha: Grada Publishing 2002: 300–310.

10. Voglova J, Kašparová P, Vrbacký F. Klinický obraz, diagnostika a diferenciální diagnostika. In: Faber E, Indrák K (eds). Chronická myeloidní leukemie. Praha: Galén Publishing 2010: 51–64.

11. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984; 63: 789–799.

12. Hasford J, Pfirmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850–858.

13. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of European Group for Blood and Marrow Transplantation. The Lancet 1998; 352: 1087–1092.

14. Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27: 6041–6051.

15. Goldman JM. Treatment strategies for CML. Best Pract Res Clin Haematol 2009; 22: 303–313.

16. Kantarjian H, Schiffer C, Jones D et al. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008; 111: 1774–1780.

17. Branford S. Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 2007: 376–382.

18. Kantarjian HM, O’Brien S, Cortes JE et al. Complete cytogenetic and molecular response to interferon-alfa-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033–1041.

19. Guilhot F, Chastang C, Michallet M et al. Interferon-alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223–229.

20. Baccarani M, Martinelli G, Rosti G et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic phase chronic myeloid leukemia. Blood 2004; 104: 4245–4251.

21. Oehler VG, Gooley T, Snyder DS et al. The effect of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782–1789.

22. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

23. Hochhaus A, O’Brien SG, Guilhot F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.

24. Deininger M, O’Brien DG, Guilhot F et al. International Randomize Study of Interferon and STI-571 (IRIS) 8-year follow-up: sustained and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood 2009; 114: 462. Abstract 1126.

25. Zackova D, Klamova H, Dusek L et al. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? Am J Hematol 2011; 86: 318–321.

26. Faber E, Mužík J, Koza V et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry. Eur J Haematol 2011; 87: 157–168.

27. Klamova H, Zackova K, Faber E et al. The Outcome of Unselected Patients with CML in Chronic Phase Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses-Population Based Analysis of 458 Patients Treated Between 2003–2009. Blood 2010; 116. Abstract 1239.

28. Mahon FX, Réa D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035.

29. Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207–3213.

30. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309.

31. O’Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242–2249.

32. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540–3546.

33. Philips D, Coutre MD, Giles FJ et al. Nilotinib in Imatinib-Resistant or Intolerant Patients with chronic myeloid leukemia in chronic phase: 48 Months Follow-Up Results of a Phase 2 Study. Blood 2011; 118. Abstract 3770.

34. Cortes JE, Kantarjian HM, Brümmendorf TH et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase chronic Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118: 4567–4576.

35. Cortes JE, Talpaz M, Bixby D et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia and other hematologic malignancies. Blood 2010; 116. Abstract 210.

36. Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 631–632.

37. Bocchia M, Lauria F. Immunotherapy of chronic myeloid leukemia. In: Cortes J, Deininger M (eds). Chronic myeloid leukemia. New York: Informa Healthcare 2007: 95–108.

38. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, version 2.2011. Available from: www.nccn.org.

39. Hochhaus A, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii63–ii64.

40. Klamová H, Voglová J. Chronická myeloidní leukemie. Transfuze Hematol Dnes 2010; 16: 17–20.

41. Klamova H, Vitek A, Michalova K et al. Interferon alfa – lék volby pro nemocné s chronickou myeloidní leukemií. Čas Lék Česk 1998; 134: 552–556.

42. Klamova H, Faber E, Žáčková D et al. Dasatinib in imatainib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. Neoplasma 2010; 57: 355–359.

43. Klamova H, Markova M, Machova K et al. Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery. Leuk Res 2009; 33: 1567–1569.